4.7 Article

Identification of a Pentasaccharide Lead Compound with High Affinity to the SARS-CoV-2 Spike Protein via In Silico Screening

Journal

Publisher

MDPI
DOI: 10.3390/ijms242216115

Keywords

SARS-CoV-2; RBD; heparan sulfate; protein binding; virtual screening

Ask authors/readers for more resources

The spike protein on the surface of the SARS-CoV-2 virus is crucial for its fusion with host cells, and heparan sulfate facilitates this fusion process. Researchers have developed a pentasaccharide library to disrupt the interaction between heparan sulfate and the receptor binding domain (RBD) of the spike protein. Molecular modeling and drug-likeness calculations were performed to assess the antiviral properties of the most promising pentasaccharide. The findings provide valuable insights for the development of HS-mimetics as potential anti-SARS-CoV-2 agents.
The spike (S) protein on the surface of the SARS-CoV-2 virus is critical to mediate fusion with the host cell membrane through interaction with angiotensin-converting enzyme 2 (ACE2). Additionally, heparan sulfate (HS) on the host cell surface acts as an attachment factor to facilitate the binding of the S receptor binding domain (RBD) to the ACE2 receptor. Aiming at interfering with the HS-RBD interaction to protect against SARS-CoV-2 infection, we have established a pentasaccharide library composed of 14,112 compounds covering the possible sulfate substitutions on the three sugar units (GlcA, IdoA, and GlcN) of HS. The library was used for virtual screening against RBD domains of SARS-CoV-2. Molecular modeling was carried out to evaluate the potential antiviral properties of the top-hit pentasaccharide focusing on the interactive regions around the interface of RBD-HS-ACE2. The lead pentasaccharide with the highest affinity for RBD was analyzed via drug-likeness calculations, showing better predicted druggable profiles than those currently reported for RBD-binding HS mimetics. The results provide significant information for the development of HS-mimetics as anti-SARS-CoV-2 agents.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available